EG-HZ vaccine / Eyegene - LARVOL DELTA

Igene, Australia Phase 1 "Safety and Immunogenicity Confirmation" for herpes zoster vaccine [Google translation] (Biospectator) - P1, N=40; NCT04210752; Sponsor: EyeGene Inc.; "Eyegene announced...that it had confirmed safety and immunogenicity in the phase 1 clinical trial of EG-HZ, a candidate for a vaccine for herpes zoster, conducted in Australia...there were no serious adverse events (SAEs) and potential risks in all 4 groups of patients receiving EG-HZ. There was no difference in adverse events (AEs) compared to the Shingrix group.there were no serious adverse events (SAEs) and potential risks in all 4 groups of patients receiving EG-HZ. There was no difference in adverse events (AEs) compared to the Shingrix group...'The domestic phase 2 clinical trial aims to apply within 2021, and it is planned to be conducted in a scale of 125 to 150 people.'"

New P2 trial • P1 data • Herpes Zoster • Infectious Disease